Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

Fig. 1

Photomicrographs of forearm skin biopsy from one patient as studied by H&E at 0 (a) and 12 (b) months and by alpha smooth muscle actin (α-SMA) at 0 (c) and 12 (d) months of treatment. This specimen demonstrates morphological improvement as evidenced by decreased thickness of collagen bundles and increased interstitial space between the collagen bundles. Decreased intensity α-SMA is seen in this specimen as well. However, when looking at all of the specimens overall, significant morphological change was not observed

Back to article page